Peter D. Senter

Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate

Kevin J. Hamblett, Peter D. Senter, Dana F. Chace et al. · Clinical Cancer Research · 2004 · 1.2K citations

Development of potent monoclonal antibody auristatin conjugates for cancer therapy

Svetlana O. Doronina, Brian E. Toki, Michael Torgov et al. · Nature Biotechnology · 2003 · 1.2K citations

Cancer Therapy, Polymer-drug Conjugate, Medicine +8

cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity

Joseph A. Francisco, Charles G. Cerveny, Damon L. Meyer et al. · Blood · 2003 · 907 citations

The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma

Peter D. Senter, Eric L. Sievers · Nature Biotechnology · 2012 · 736 citations

Tumor Biology, Lymphoid Neoplasia, Medicine +8

Enhanced Activity of Monomethylauristatin F through Monoclonal Antibody Delivery:  Effects of Linker Technology on Efficacy and Toxicity

Svetlana O. Doronina, Brian A. Mendelsohn, Tim D. Bovee et al. · Bioconjugate Chemistry · 2005 · 506 citations

Mab Degradation, Immunology, Immunotherapy +19